Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Colbath

Sports Medicine Gaffney, SC Medical Doctor

NPI 1386841617 CMS profile 199333

1552 N Limestone St Ste B, Gaffney, SC 29340

Open in the dashboard

General payments

$36,053

204 records reported · program years 2019–2025

Research payments

$44,791

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Colbath of Gaffney, SC is reported in the CMS Open Payments database as having received $36,053 across 204 general payments and $44,791 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,584 41
2025 Research $32,791 6
2024 General $14,301 63
2024 Research $12,000 1
2023 General $6,360 29
2022 General $6,632 26
2021 General $490 10
2020 General $144 3
2019 General $2,542 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Colbath
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Gregory Colbath were reported at $5,584. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Gregory Colbath Sports Medicine median Middle half National median
2019 $2,542 $1,176 $199–$4,249 $163
2020 $144 $708 $96–$2,890 $114
2021 $490 $1,213 $152–$3,994 $132
2022 $6,632 $1,230 $159–$3,998 $149
2023 $6,360 $584 $146–$2,836 $160
2024 $14,301 $628 $163–$3,168 $164
2025 $5,584 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Linvatec Corporation $15,167 43 payments
  2. Zimmer Biomet Holdings, Inc. $6,097 42 payments
  3. Peerless Surgical Inc. $3,981 9 payments
  4. Pacira Pharmaceuticals Incorporated $3,287 13 payments
  5. Arthrex, Inc. $1,548 3 payments
  6. Smith+Nephew, Inc. $1,297 15 payments
  7. Stryker Corporation $715 8 payments
  8. Amgen Inc. $710 18 payments
  9. Miach Orthopaedics, Inc. $652 3 payments
  10. Anika Therapeutics, Inc. $578 8 payments
  11. Other $2,022 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $18,796 36 payments
  2. Food and Beverage $10,096 161 payments
  3. Education $4,461 5 payments
  4. Honoraria $2,700 2 payments
Products named General payments · program years 2019–2025
  1. BIOBRACE 23MM $14,250 37 payments
  2. Exparel $3,008 9 payments
  3. Comprehensive Shoulder System $2,709 19 payments
  4. Iovera $2,645 7 payments
  5. LINVATEC SHOULDER ARTHROSCOPY $2,459 10 payments
  6. Zilretta $2,446 2 payments
  7. Inverse/Reverse Screw System $886 1 payment
  8. INSPACE $560 5 payments
  9. Q-FIX $441 1 payment
  10. Latarjet System $441 1 payment
  11. Other $6,916 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Linvatec Corporation $44,791 7 payments

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$139,375

Of which drugs: $16,757

Medicare patients

369

Average age 75

Services billed

3,449

196 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 73%
Diabetes 31%
Chronic kidney disease 27%
Atrial fibrillation 25%
Ischemic heart disease 23%
Osteoporosis 23%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 15 1,200 $6,241
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 98 528 $385

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $1,125
$1,125 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $815
$815 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record